What risk is increased primarily due to steroid treatment in clients with ITP?

The correct answer highlights that the risk of infection is notably increased in clients receiving steroid treatment for Immune Thrombocytopenic Purpura (ITP). Corticosteroids, commonly used in managing ITP, can suppress the immune system. This immunosuppressive action diminishes the body’s ability to fight off infections, making patients more susceptible to bacterial, viral, and fungal infections.

Patients on steroids must be closely monitored for any signs of infection due to this increased risk. Elevated blood sugar levels, delayed wound healing, and changes in normal inflammatory responses are also side effects associated with steroid treatment, which can further contribute to the heightened danger of infections.

In the context of the other response options, while conditions like dehydration, fractures, and heart disease may also be concerns for patients receiving steroid therapy, the most immediate and clinically significant risk in the context of ITP treatment is the increased susceptibility to infections. This understanding is crucial in clinical practice, guiding healthcare providers to implement appropriate preventative measures for these patients.